Achieve Life Sciences, Inc. Convertible Debt, Noncurrent
Achieve Life Sciences, Inc. (ACHV) had Convertible Debt, Noncurrent of $7.46 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:ConvertibleDebtNoncurrent · last filed 2026-08-11
- 2026-06-30: Convertible Debt, Noncurrent $7.46M.
- 2026-03-31: Convertible Debt, Noncurrent $9.32M.
- 2025-12-31: Convertible Debt, Noncurrent $11.19M.
- 2025-09-30: Convertible Debt, Noncurrent $8.67M.
| Period end | Convertible Debt, Noncurrent |
|---|---|
| 2026-06-30 | $7.46M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $9.32M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $11.19M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $8.67M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $8.66M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $8.66M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $9.84M 10-K · filed 2026-03-24 |
| 2024-09-30 | $9.82M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $8.80M 10-Q · filed 2024-08-13 |
| 2023-09-30 | $16.20M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $15.73M 10-Q · filed 2023-08-14 |
| 2022-09-30 | $15.76M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $15.46M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $15.17M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $14.92M 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |